Equity and Capital Reserves - The company's total equity at the end of the period was RMB 2,760,533,834.44, with a capital reserve of RMB 48,031,378.12[2] - The company increased its registered capital by RMB 3,780,000 in 2011 through capital reserve conversion, bringing the total registered capital to RMB 189,000,000[6] - In 2016, the company increased its registered capital by RMB 122,359,164.00 through capital reserve conversion, followed by a reduction of RMB 93,829.00 due to restricted stock repurchase, resulting in a final registered capital of RMB 530,129,216.00[7] - The company's total equity at the beginning of the period was RMB 2,903,595,282.21, with a capital reserve of RMB 186,869,930.14[14] - The company's total equity at the end of the period was RMB 3,163,270,155.62, with a capital reserve of RMB 415,736,937.67[5] - In 2015, the company increased its registered capital by RMB 87,107,693.00 through capital reserve conversion, bringing the total registered capital to RMB 377,466,671.00[16] - The company increased its registered capital by RMB 640,900.00 in July 2017, bringing the total registered capital to RMB 712,522,480.00[17] - In 2019, the company reduced its registered capital by RMB 21,383.00 due to the repurchase and cancellation of restricted shares, and then increased it by RMB 315,089,530.00 in May 2020, resulting in a total registered capital of RMB 1,365,387,965.00[18] - The company's registered capital increased by RMB 34,792,400.00 to RMB 1,673,257,958.00 due to the third phase of restricted stock incentive plan[140] Financial Performance and Income - The company's comprehensive income for the period was RMB 344,449,829.75, contributing to a total equity increase of RMB 120,778,492.69[14] - The company's net profit attributable to the parent company for the period was RMB 344,449,829.75, with minority shareholders' equity increasing by RMB 7,363,500.86[14] - Revenue for the reporting period was 1.287 billion yuan, a year-on-year increase of 19.11%[133] - Net profit attributable to shareholders of the listed company was 396.36 million yuan, a year-on-year increase of 15.07%[133] - Net cash flow from operating activities was 332.9 million yuan, a year-on-year increase of 40.93%[133] - Basic earnings per share were 0.24 yuan, a year-on-year increase of 14.29%[133] - The weighted average return on equity was 12.05%, an increase of 0.15 percentage points year-on-year[133] - The company's net profit for the first half of 2023 was RMB 379,863,083.54, an increase from RMB 345,621,168.58 in the same period of 2022[152] - Comprehensive income for the first half of 2023 reached 396.36 million yuan, contributing to total owner's equity of 3.4 billion yuan[156] - Parent company achieved revenue of 918.2073 million yuan, a year-on-year increase of 29.76%, with growth hormone product sales revenue increasing by 31.62%[181] - Parent company's net profit was 379.8631 million yuan, a year-on-year increase of 9.91%, with operating cash flow of 321.3585 million yuan, up 104.10%[181] - Four subsidiaries (余良卿, 安科恒益, 苏豪逸明, 安科华捷) achieved combined revenue of 344.605 million yuan, up 3.33%, with combined net profit of 37.4636 million yuan, up 10.39%[181] Cash Flow and Financial Management - The company's investment amount for the reporting period was RMB 752,710,744.94, a decrease of 4.01% compared to the same period last year[22] - The company's entrusted financial management totaled RMB 106,536, with an outstanding balance of RMB 73,290.08[23] - Operating cash flow for the first half of 2023 was RMB 332,899,560.43, up from RMB 236,208,928.14 in the same period of 2022[153] - Cash received from selling goods and providing services in the first half of 2023 was RMB 1,179,963,253.14, compared to RMB 1,041,496,656.36 in the same period of 2022[153] - Investment cash flow for the first half of 2023 was RMB 10,399,565.60, a significant improvement from a negative RMB 6,482,293.53 in the same period of 2022[153] - Cash paid for goods and services in the first half of 2023 was RMB 163,694,097.82, slightly lower than RMB 164,181,762.57 in the same period of 2022[153] - Cash paid to and for employees in the first half of 2023 was RMB 298,258,383.60, up from RMB 254,488,667.68 in the same period of 2022[153] - The company's total operating cash inflow for the first half of 2023 was RMB 1,183,476,049.11, compared to RMB 1,080,138,711.00 in the same period of 2022[153] - Operating cash flow increased by 104.1% to 321.4 million yuan in the first half of 2023 compared to 157.5 million yuan in the same period last year[154] - Investment cash flow decreased by 81.5% to 28.1 million yuan in the first half of 2023 from 152.4 million yuan in the same period last year[154] - Financing cash flow showed a net outflow of 413.95 million yuan in the first half of 2023, compared to 317.16 million yuan outflow in the same period last year[154] - Cash and cash equivalents decreased by 70.73 million yuan to 253.46 million yuan at the end of June 2023[154] - The company's monetary funds decreased from 324,586,628.66 RMB to 275,605,526.68 RMB, a decrease of 15.1%[165] - Monetary funds decreased by 1.15% to 275,605,526.68 yuan, accounting for 6.48% of total assets[192] Subsidiaries and Investments - A new subsidiary, Hangzhou Yugao Pediatric Clinic Co., Ltd., was established and included in the consolidated financial statements for the period from March to June 2023[10] - The company holds 72.5353% direct stake in Anhui Anke Yu Liangqing Pharmaceutical Co., Ltd. and 100% indirect stake in Anhui Yu Liangqing Health Industry Co., Ltd.[141] - The company's subsidiary, Zhongdemeilian, has obtained more than 60 invention patents and won multiple awards, including the National Science and Technology Progress Award[164] - The company's subsidiary, Yuliangqing, is a "Century-old Brand" recognized by the Ministry of Commerce and has been selected as a specialized and innovative enterprise in Anhui Province[170] - The company's subsidiary, Zhongdemeilian, is a leader in forensic DNA testing in China, having developed the most comprehensive series of forensic DNA testing kits globally, breaking foreign technology monopolies[171] - The company's subsidiary, Suhao Yiming, is a high-tech enterprise in Shanghai and a supplier of national standard products, specializing in the R&D, production, and sales of peptide APIs, with 7 registered API products and 2 EU CEP products[171] - The company's subsidiary, Anke Hengyi, focuses on chemical synthetic drugs, with products like amoxicillin granules and capsules for treating infections caused by sensitive bacteria[175] - Subsidiary Anke Hengyi completed bioequivalence clinical studies for cefaclor dispersible tablets and obtained production approval for cefdinir granules[184] - Suhao Yiming, a subsidiary, is a leading domestic peptide API manufacturer with 30 national invention patents and a competitive advantage in solid-phase peptide synthesis technology[188] Research and Development - The company completed 6 functional food R&D projects and assisted in production during the reporting period[159] - 9 self-developed projects and 3 cooperative projects were carried out in the first half of 2023, with 5 forensic DNA testing projects completed[159] - The company completed BE filing, bioequivalence testing, and stability sample testing for Flurbiprofen Gel Patch during the reporting period[159] - The company is actively optimizing traditional Chinese medicine patches and accelerating functional food development in the health industry[159] - Parent company's R&D expenses reached 76.6277 million yuan, a year-on-year increase of 86.65%[181] - The company is advancing the industrialization of PEGylated recombinant human growth hormone injection and recombinant anti-VEGF humanized monoclonal antibody injection[183] - The company established a strategic partnership with Hefei Afana Biotechnology to develop mRNA vaccines and drugs, with a COVID-19 Omicron variant mRNA vaccine receiving clinical trial approval in August 2023[184] - The company is advancing the industrialization of multiple targeted anti-tumor drugs, including "ZG033 Injection"[200] - The company is actively exploring other target areas such as bispecific antibodies, ADC, and mRNA drug technology platforms to enrich its R&D pipeline[200] Financial Instruments and Accounting Policies - The company's financial guarantee contract liabilities are measured at the higher of the loss provision amount determined based on the impairment principles of financial instruments and the initial recognition amount minus the cumulative amortization amount determined based on revenue recognition principles[35] - The company's financial assets classified as measured at fair value through other comprehensive income are managed with the business model of both collecting contractual cash flows and selling financial assets[45] - The company's consolidated financial statements reflect the overall financial position, operating results, and cash flows of the enterprise group, prepared in accordance with relevant accounting standards and unified accounting policies[28] - The company has designated certain non-trading equity instrument investments as financial assets measured at fair value through other comprehensive income, with only dividend income recognized in current profits and losses[53] - Derivative financial instruments are measured at fair value, with gains or losses from changes in fair value directly recognized in current profits and losses, except for the effective portion of cash flow hedges[54] - Foreign currency transactions are translated using the exchange rate at the transaction date, with exchange differences recognized in current profits and losses for monetary items at the balance sheet date[55] - The company calculates expected credit losses for other receivables by considering historical credit loss experience, current conditions, and future economic forecasts[57] - Financial assets not measured at amortized cost or fair value through other comprehensive income are classified as financial assets measured at fair value through profit or loss, with all fair value changes recognized in current profits and losses[59] - The company measures expected credit losses for financial instruments at each balance sheet date, categorizing them into three stages based on credit risk[65] - For financial assets with objective evidence of impairment, the company conducts individual impairment tests and recognizes expected credit losses, while grouping other receivables based on credit risk characteristics[67] - The company's financial instruments are classified and measured based on their characteristics, including financial assets at fair value through profit or loss[102] - The company uses historical credit loss experience and forward-looking information to calculate expected credit losses for receivables financing and long-term receivables[78][82] - The company adjusts capital reserves when minority shareholders of subsidiaries increase capital, diluting the parent company's equity ratio[95] - The company recognizes income and expenses related to joint operations based on its share of the arrangement[97] - The company terminates the recognition of financial liabilities when the present obligation is discharged or the terms are substantially modified[79] - The company reclassifies other comprehensive income related to equity investments in subsidiaries as current profit or loss when control is lost[90] - The company consolidates financial statements by eliminating the effects of internal transactions between parent and subsidiaries[109] - The company uses the equity method to account for investments in joint ventures[87] - The company adjusts the carrying amount of assets and liabilities in consolidated financial statements to reflect changes in minority interests[93] - The company determines cash and cash equivalents based on specific criteria[72] Environmental and Operational Compliance - The company's environmental protection department is responsible for the daily operation and maintenance of the sewage treatment station, ensuring that industrial wastewater is treated and discharged in compliance with environmental standards[25] - The company's wastewater treatment station ensures that industrial wastewater is treated to meet standards before being discharged into the Anqing City wastewater treatment plant, with no instances of exceeding discharge limits reported[52] Product Development and Market Recognition - The company's main product, human interferon α2b "Andafen," has multiple dosage forms and high market recognition, with ongoing innovation in indications and dosage forms. The new human interferon α2b spray for treating pediatric herpangina is in Phase II clinical trials[170] - The company's human growth hormone "Ansuman" has a high patient compliance rate and its market share in China is increasing year by year[170] - The company's first antibody drug, trastuzumab injection, is in the registration review and approval stage for treating HER2-high breast and gastric cancers[170] - The company's second anti-tumor monoclonal antibody, recombinant anti-VEGF humanized monoclonal antibody injection, is in the preparation stage for production application, targeting advanced non-small cell lung cancer and colorectal cancer[170] - The company's self-developed recombinant human growth hormone-Fc fusion protein injection has completed Phase I clinical trials and is preparing for Phase II trials, with no Fc fusion protein long-acting growth hormone currently on the market globally[170] Risks and Strategic Plans - The company plans not to distribute cash dividends, issue bonus shares, or convert capital reserve into share capital[124] - The company faces risks such as potential delays in new drug development, industry policy changes, and risks associated with business integration and scale expansion[124] - The company's management will actively monitor industry policy changes, increase new product development efforts, and improve operational efficiency to maintain sustainable development[43] Assets and Liabilities - Total assets at the end of the reporting period were 4.253 billion yuan, a slight decrease of 0.10% compared to the end of the previous year[133] - Trade receivables increased from 404,927,807.50 RMB to 480,377,893.47 RMB, an increase of 18.6%[165] - Inventory increased from 210,477,722.04 RMB to 238,450,923.82 RMB, an increase of 13.3%[165] - Total current assets decreased from 1,910,534,698.21 RMB to 1,854,095,806.78 RMB, a decrease of 2.9%[165] - Long-term equity investments decreased from 196,406,298.83 RMB to 188,557,565.83 RMB, a decrease of 4.0%[166] - Fixed assets decreased from 700,121,972.21 RMB to 680,558,485.25 RMB, a decrease of 2.8%[166] - Development expenditure increased from 405,862,721.41 RMB to 422,878,292.11 RMB, an increase of 4.2%[166] - Total liabilities decreased from 855,166,124.71 RMB to 823,518,726.25 RMB, a decrease of 3.7%[166] - Total equity increased from 3,401,677,387.74 RMB to 3,429,045,961.75 RMB, an increase of 0.8%[166] - Accounts receivable increased by 1.78% to 480,377,893.47 yuan, accounting for 11.30% of total assets[192] - Inventory increased by 0.66% to 238,450,923.82 yuan, accounting for 5.61% of total assets[192] Dividends and Shareholder Returns - The company has accumulated cash dividends of over 1.827 billion yuan since its listing in 2009, which is 1.86 times the total funds raised from the public[199] - The cash dividend for 2022 accounted for 59.33% of the net profit attributable to the parent company's owners[199] Non-Recurring Gains and Losses - Non-recurring gains and losses amounted to 13.29 million yuan in the first half of 2023, mainly from government subsidies and financial asset transactions[160] - Investment income and fair value change gains amounted to 1,906,115.43 yuan, accounting for 0.41% of total profit, primarily due to equity method investment gains and bank financial product investment income[192] - Fair value change losses were -1,858,898.41 yuan, accounting for -0.40% of total profit, mainly due to changes in the fair value of financial assets and the transfer of previously recognized fair value gains to investment income[192] Contract Fulfillment and Revenue Recognition - The company's contract fulfillment costs are recognized as assets when they increase resources for future fulfillment obligations[118]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 594,174,209.84, representing a year-on-year increase of 11.40% compared to CNY 533,355,253.62 in the same period last year[27]. - The net profit attributable to shareholders of the listed company for Q1 2023 was CNY 185,618,139.71, reflecting a year-on-year growth of 7.36% from CNY 172,897,830.23[27]. - The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY 178,156,883.51, up 12.68% from CNY 158,108,566.09 in the previous year[27]. - The net cash flow from operating activities increased by 31.35% to CNY 215,982,444.58, compared to CNY 164,433,196.39 in the same period last year[27]. - The company's total assets at the end of the reporting period were CNY 4,480,329,008.05, a 5.29% increase from CNY 4,255,325,817.63 at the end of the previous year[27]. - Total operating revenue for Q1 2023 reached ¥594,174,209.84, an increase of 11.43% compared to ¥533,355,253.62 in Q1 2022[38]. - Net profit for Q1 2023 was ¥188,850,882.44, representing a growth of 6.66% from ¥176,960,698.62 in Q1 2022[39]. - The total equity attributable to shareholders of the parent company increased to ¥3,419,565,300.37, compared to ¥3,208,622,822.65 in the previous year, reflecting a growth of 6.55%[38]. - The total assets as of Q1 2023 were ¥4,480,329,008.05, an increase from ¥4,255,325,817.63 in Q1 2022[38]. - The total liabilities as of Q1 2023 were ¥858,070,682.60, slightly up from ¥853,615,750.74 in Q1 2022[38]. Research and Development - The company's R&D investment has increased, contributing to the continuous progress of R&D projects, which supports high-quality development[28]. - The company's R&D expenses increased to ¥35,377,092.33, a rise of 22.06% compared to ¥28,996,807.93 in the same period last year[39]. - Research and development expenses for the period amounted to ¥35,377,100, representing a 22.0% increase compared to the previous year[43]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 65,387[32]. - The largest shareholder, Song Lihua, holds 26.55% of shares, totaling 444,278,710 shares[32]. - The largest shareholder, Song Liming, holds 6.87% of shares, totaling 114,889,420 shares[32]. - The company is unaware of any other relationships or concerted actions among the top 10 shareholders, except for the relationship between Song Lihua and Song Liming[33]. Cash Flow and Liquidity - The company's cash and cash equivalents increased to ¥373,617,457.87 from ¥324,586,628.66 at the beginning of the year, a growth of approximately 15.5%[37]. - The cash and cash equivalents at the end of the period increased to ¥373,216,910.33 from ¥207,474,291.92, marking a significant improvement in liquidity[41]. - The net cash flow from investment activities was negative at -¥173,330,460.50, an improvement from -¥294,123,232.06 in the previous year, reflecting a 41.07% increase in cash flow from investments[47]. - In Q1 2023, the company's operating cash inflow totaled ¥558,257,243.14, an increase from ¥530,877,155.94 in the previous year, reflecting a growth of approximately 5.5%[41]. Operating Costs and Expenses - Total operating costs amounted to ¥377,413,240.03, up 10.52% from ¥341,436,111.47 in the previous year[39]. - The company's management expenses increased by 36.27% year-on-year, mainly due to the amortization of equity incentive expenses related to the restricted stock incentive plan[29]. - The company reported a decrease in sales expenses to ¥149,534,885.84, down 13.73% from ¥173,371,294.63 in Q1 2022[39]. - The company's tax expenses for Q1 2023 were ¥31,012,990.63, up from ¥27,592,749.01 in the same period last year[39]. Other Income and Investment - Other income decreased by 70.88% year-on-year, primarily due to a significant amount of government subsidies received in the same period last year[3]. - The company's investment income for Q1 2023 decreased by 82.46% year-on-year, attributed to significant changes in the investment income recognized from long-term equity investments[22]. - The company’s investment income for Q1 2023 was ¥431,079.56, a decrease from ¥2,458,005.94 in the previous year[39]. - The fair value change income decreased by 73.75% year-over-year, primarily due to the recovery of financial products that had significant fair value adjustments in the previous year[46]. Shareholder Equity and Restricted Shares - The total number of restricted shares at the beginning of the period was 513,769,070, with 2,693,000 shares released during the period, resulting in an ending balance of 511,494,801 shares[50]. - The company has a total of 34,792,400 shares under the third phase of the restricted stock incentive plan, which has completed registration and will be executed according to the relevant regulations[50]. - The number of shares held by key executives includes 325,934,032 shares for Song Lihua, with 2,425,000 shares released during the period[49]. - The company reported that 383,631 shares were added to Wang Yong's holdings during the reporting period, as he was elected as a supervisor[50]. - The total number of shares held by Zhao Hui decreased from 7,527,375 to 7,478,375 after releasing 49,000 shares[49]. - The company has a policy that allows executives to release 25% of their shares at the end of the previous year during their tenure[49]. - The total number of shares held by Liu Chunyan increased to 140,400 after adding 35,100 shares during the reporting period[50]. - The company has implemented a six-month lock-up period for shares held by executives after their term ends[49]. - The total number of shares held by Li Kun is 129,565, with no shares released during the period[50]. - The company continues to adhere to the regulations regarding the release of restricted shares for executives, ensuring compliance with corporate governance standards[49].

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2023-002 | 投资者 | □特定对象调研 □分析师会议 | | | | | --- | --- | --- | --- | --- | | 关系活 | □媒体采访 √业绩说明会 | | | | | 动类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | 参与单 | 线上参与安科生物 2022 年度业绩网上说明会的投资者 | | | | | 位名称 | | | | | | 及人员 | | | | | | 姓名 | | | | | | 时间 | 2023 年 04 月 12 日（星期三）15:00-17:00 | | | | | 地点 | 同 顺 路 平 台 （ 网 址 | 花 | 演 | ： | | | https://board.10jqka.com.cn/rs/pc/detail?roadshowId=1004833） | | | | | 上市公 | 董事长兼总裁：宋礼华先生 | | | | | ...

安徽安科生物工程（集团）股份有限公司（以下简称"公司"）已于 2023 年 3 月 28 日披露了公司 2022 年年度报告及其摘要。为便于广大投资者更加全面 深入地了解公司 2022 年度经营业绩及发展战略等情况，公司将于 2023 年 4 月 12 日（星期三）15:00-17:00 在"同花顺路演平台" 采用网络远程方式举行 2022 年度业绩网上说明会。 投资者可以通过以下两种方式参与：1）登录同花顺路演平台，进入直播间 https://board.10jqka.com.cn/rs/pc/detail?roadshowId=1004833 进行提问；2）使用同 花顺手机炒股软件扫描下方二维码进入路演直播间进行提问互动交流。 出席本次业绩说明会的人员有：公司董事长、总裁宋礼华先生，独立董事刘 光福先生，高级副总裁姚建平先生，董事、财务总监汪永斌先生，董事、董事会 秘书李坤先生，副总裁窦颖辉先生。 为广泛听取投资者的意见和建议，提升交流的针对性，现就公司 2022 年度 业绩说明会提前向投资者公开征集问题。提问通道自本公告发出之日起开放，投 资者通过上述参与方式进入"安科生物 2022 年度业绩网上说明会 ...

安徽安科生物工程(集团)股份有限公司 1 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个 别和连带的法律责任。 | --- | |-------------------------------------------------------------------------------------| | | | 中带量采购导致药品降价的风险、业务整合、规模扩大带来的集团化管理风 | | 险等，有关风险因素内容已在本报告中第三节 " 管理层讨论与分析 " 之 | | 公司未来发展的展望 " 部分予以描述，敬请广大投资者注意投资风险。 | | 公司经本次董事会审议通过的利润分配预案为：以 1,669,070,552 | | 向全体股东每 10 股派发现金红利 2.50 元（含税），送红股 0 股（含税），以 | | 资本公积金向全体股东每 10 股转增 0 股。 | | --- | |------------------------------------------------------------------------- ...